



Acquisition of product portfolio from Roche completed

- Competition authorities have approved the acquisition
- Meda's position in key therapy areas strengthened
- Sales level of about 500 MSEK
- Purchase price 120 MEUR, equivalent to about 2,3 times sales

On 15 August 2008, Meda announced that it reached agreement regarding acquisition of four well established pharmaceuticals from the Swiss pharma company Roche - pending approval from competition authorities. The authorities have now approved the purchase, and Meda is taking over the products.

The acquired products have strong brand names and the total sales level is 500 MSEK. No employees will transfer from Roche to Meda in conjunction with the acquisition. Meda acquires world-wide rights to the products and the most important markets are Germany, Spain, Switzerland, USA and France. Meda strengthens its position in key therapy areas; Cardiology, CNS and Pain / Inflammation.

The purchase price is 120 MEUR, corresponding to approximately 1 160 MSEK and equivalent to about 2,3 times sales. An up-front of 110 MEUR has been paid at closing of the transaction and the remaining 10 MEUR will be paid upon completion and assignment of certain agreements.

The four acquired Roche products are;

	Active substance	Medical use	Therapy area
Marcoumar	Phenprocoumon	Anticoagulant	Cardiovascular
Torem	Torasemide	Loop diuretic	Cardiovascular
Tilcotil	Tenoxicam	Rheumatoid and osteoarthritis	Pain / Inflammation
Aurorix	Moclobemide	Antidepressant	Central nervous system (CNS)

Marcoumar (*phenprocoumon*) is a well-established anticoagulant. This product fits perfectly into Meda's cardiovascular product portfolio. The largest market is Germany and the total sales level is about 200 MSEK.

Torem (*torasemide*) is a loop diuretic. It is also marketed using trademarks such as Demadex, Dilutol and Toradiur in more than 30 countries – also in the USA and in Japan. The product fits well in Meda's antihypertensive product range. The sales level is about 180 MSEK.

Tilcotil (*tenoxicam*) is a NSAID drug for the treatment of painful inflammatory and degenerative disorders of the musculoskeletal system such as rheumatoid and osteoarthritis, and arthrosis. The product is also marketed using the trademarks Mobiflex, Tilatil, Tilcitin and Alganex. Tilcotil fits perfectly into Meda's therapy area Pain / Inflammation. The sales level is approximately 70 MSEK.

Aurorix (*moclobemide*) is a MAO-A inhibitor and a well-known antidepressant for specialists to prescribe. The sales level is approximately 50 MSEK.

For more information, please contact:

Anders Larnholt, Vice President Investor Relations, tel. +46 709 458 878

MEDA AB (publ) is a leading international specialty pharma company. The company specialises in marketing and pharmaceutical development in late clinical stage. Acquisitions and long-term partnerships are fundamental factors that drive the company's strategy. Meda is represented by its own organisations in about 40 countries. Meda's products are sold in 120 countries worldwide. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit www.meda.se.